VEGFA and cancer: Preclinical studies demonstrated that lenvatinib, a multiple receptor TKI targeting VEGF and FGF receptors, increased IFN-γ+ and granzyme B+ CD8+ T cells, which improved cancer immunotherapy when combined with PD-1 blockade, and its combination therapy with pembrolizumab has approved by FDA for patients with advanced EC [291].